A pioneering clinical trial spearheaded by the Abramson Cancer Center of the University of Pennsylvania has demonstrated the potential to identify breast cancer survivors at higher risk of recurrence due to the presence of dormant cancer cells. This groundbreaking research offers an effective strategy to treat these cells using repurposed existing medications, as published in Nature Medicine.
Understanding Dormant Cancer Cells
As breast cancer survival rates improve thanks to advancements in detection and treatment modalities, the challenge of cancer relapse persists. For the approximately 30% of individuals diagnosed with breast cancer who experience a relapse, the prognosis can be dire. These relapses often require continuous treatment that cannot fully eradicate the cancer.
The phenomenon of dormant cancer cells poses a significant risk. Some breast cancers, such as triple-negative and HER2-positive types, tend to recur within a few years, while hormone receptor-positive (ER+) cancers can recur decades later. Previously, no methods existed to effectively identify patients harboring these dormant cells in real-time, complicating the prevention of incurable relapse.
Key Findings of the Clinical Trial
The recent randomized Phase II trial included 51 breast cancer survivors who had completed their treatment within the previous five years. The study demonstrated that existing medications cleared dormant tumor cells from approximately 80% of participants.
The three-year survival rate without any disease recurrence was noteworthy, with results showing above 90% survival among patients who received a single treatment drug and a perfect 100% for those who received a combination therapy of both study drugs.
The Words of an Expert
“The lingering fear of cancer returning is something that hangs over many breast cancer survivors after they celebrate the end of treatment. Our study shows that preventing recurrence by monitoring and targeting dormant tumor cells is a strategy that holds real promise."
— Dr. Angela DeMichele, Principal Investigator
Mechanism of Dormant Tumor Cells
Research indicates that these so-called "sleeper cells," or minimal residual disease (MRD), can remain latent for years before potentially reactivating. This dormancy complicates detection, as these cells may not appear on standard imaging tests commonly used to track cancer recurrence.
Once reactivated, these cells can proliferate and ultimately contribute to the dissemination of metastatic breast cancer. Patients with MRD exhibit a higher likelihood of experiencing recurrence, coupled with a decrease in overall survival rates.
Preclinical Research Insights
The research team conducted extensive preclinical studies in mice, revealing that the underlying mechanisms allowing tumor dormancy include autophagy and mTOR signaling pathways. Two FDA-approved drugs, initially intended for other conditions, showed effective results in clearing MRD during these animal trials.
Clinical Trials and Future Directions
DeMichele's team developed a systematic approach to screen breast cancer survivors for dormant tumor cells in their bone marrow following treatment completion. Patients identified with MRD were subsequently enrolled in the Phase II CLEVER clinical trial, which randomized participants to receive either monotherapy with one of the two drugs or a combination treatment.
The results revealed that treatment cleared dormant tumor cells in the majority of participants after a period of six to twelve months, with just two patients experiencing a cancer recurrence after a median follow-up of 42 months.
Advancements in Cancer Treatment
This innovative approach diverges from the traditional 'wait and see' mentality that often accompanies the conclusion of breast cancer treatments. DeMichele expressed hope that this research encourages further exploration in the field of dormant tumor cell targeting.
The clinical team is actively enrolling patients in larger ongoing studies designed to validate and extend the promising findings from the CLEVER trial.
Conclusion and Citation
The findings outlined in the study signify a substantial advancement in the fight against breast cancer recurrence. By targeting dormant cancer cells before they can proliferate as aggressive forms of the disease, new avenues of treatment may significantly enhance patient outcomes.
For more detailed insights, refer to the original study titled Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial published in Nature Medicine (2025).
Additional Information
This research was facilitated by collaborations and is ongoing in multiple cancer centers across the country. For readers interested in further studies regarding breast cancer treatment and survivor outcomes, resources such as the National Cancer Institute provide extensive information.
Author: Sadie Harley, Scientific Editor - Reviewed by Robert Egan, Associate Editor
Discussion